Connect with us

Legal & Regulation

New Jersey Governor Promises to Sign Use Medical Cannabis Act into Law

Published

on

New Jersey Governor Promises to Sign Use Medical Cannabis Act into Law

In a ceremony in Freehold that was attended by Phil Murphy, the New Jersey Governor revealed some interesting news to the cannabis world. The governor confirmed that he will sign the Jake Honig Compassionate Medical Cannabis Use Act into law tomorrow.

The law unites the 3421 Assembly Bill with the 1955 Senate Bill. A seven-year-old cancer victim is the inspiration of the law, and it is named after him.

The bill has removed certain restrictions on medical marijuana access. This was in an attempt to improve on the experience and deal with the suffering most New Jersey patients like Honig go through. Honigs family will be present during the signing of the bill into law.

Honig law will significantly see the opening of medical marijuana in New Jersey. There are also plans by the state to dish out some more 108 licenses to the marijuana businesses. For now, the state only has 12 integrated licenses with only half of them working. There will be 30 permits for processing, 54 permits for the dispensary department, and 24 cultivation licenses throughout the state.

The 12 already licensed companies that work in New Jersey will be required to get the new permit that would help them cement their footprint in the marijuana business in the state.

Murphy said that barriers need to be knocked down to make medical marijuana a reality, affordable, and accessible. Murphy is a cannabis industry pioneer and has been campaigning for lesser stringent marijuana laws.

Patients monthly intake will be increased to 3 ounces by the new law; the law will also enable the purchase of cbd oils and edibles by New Jersey residents with medical marijuana cards.

New licenses can be applied by Businesses that are known as the Alternative Treatment Centers. The Health Department in New Jersey stated that patients are very eager for affordable therapy and access to the herb. This is substantially a huge win for the marijuana campaign.

Recreational marijuana use had been brought to the Senate by Murphy and his cannabis advocates, but the deal didn’t go through this year. There was minimal support for the bill. The tax incentive program clashed the bill nonetheless lawmakers are planning on adult-use cannabis legalization stated for next year to a public ballot.

There is another bill that seeks to put to an end the criminalization of cannabis use. This bill will also remove any background criminal records of previously cannabis offenders.

Emma Jay is one of the most esteemed suppliers of TOC cannabis content who loves to find facts and figures as well as stuff plenty of statistics and tidbits backed by research. Stemming with authenticity as a Certified HIPAA Professional in healthcare, Section 504 Coordinator Certificate in Legal and Certified Housing Asset Manager in Real Estate. Boasting over a decade-long stint in community healthcare, EJ will now be helping carry the TOC torch into the future.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.